全自动化学发光法检测颗粒体蛋白前体的分析性能与临床价值
研究验证了Chorus Evo全自动化学发光免疫分析法检测血浆颗粒体蛋白前体(PGRN)的分析性能,并评估其对GRN突变携带者的鉴别能力。结果显示该方法批内和批间精密度可接受,GRN+携带者PGRN水平显著低于对照组及其他突变携带者,ROC曲线下面积达0.985。
要点
- 新全自动PGRN检测方法分析性能稳健,适合临床实验室常规使用。
- GRN+携带者血浆PGRN中位数显著低于对照组和GRN-携带者。
- PGRN水平可高精度区分GRN+与GRN-携带者,AUC为0.985。
核心结论
- 新全自动PGRN检测方法分析性能稳健,适用于临床环境,可辅助神经退行性疾病患者的鉴别诊断。
研究设计与样本
- 采用Chorus Evo全自动化学发光免疫分析法,检测5份血浆池及25名对照和151例不同神经退行性疾病患者的残余血浆样本,其中61例患者进行了GRN基因筛查。
主要发现
- 批内精密度CV%范围为3.8%(11.5 pg/L)至10.8%(2.5 pg/L),批间精密度CV%范围为5.6%(68.7 pg/L)至10.7%(2.8 pg/L)。
- 61例基因筛查患者中,3例为GRN+携带者,18例为其他突变携带者,40例为无突变携带者。
- GRN+携带者PGRN中位数(15.9 pg/L)显著低于对照组(32.8 pg/L;p=0.006)、GRN-携带者(27.50 pg/L;p=0.007)、其他突变携带者(24.80 pg/L;p=0.05)及神经退行性疾病患者(22.40 pg/L;p=0.05)。
- ROC分析显示PGRN水平区分GRN+与GRN-携带者的AUC为0.985,区分GRN+与其他突变携带者的AUC为0.870。
关键数值与推荐
- 批内精密度CV%:3.8%(11.5 pg/L)至10.8%(2.5 pg/L);批间精密度CV%:5.6%(68.7 pg/L)至10.7%(2.8 pg/L)。
- GRN+携带者PGRN中位数15.9 pg/L,对照组32.8 pg/L(p=0.006),GRN-携带者27.50 pg/L(p=0.007),其他突变携带者24.80 pg/L(p=0.05),神经退行性疾病患者22.40 pg/L(p=0.05)。
- 区分GRN+与GRN-携带者的AUC为0.985;区分GRN+与其他突变携带者的AUC为0.870。
临床怎么用
- 该自动化PGRN检测方法可用于临床实验室,帮助临床医生对神经退行性疾病患者进行鉴别诊断,尤其是识别GRN相关额颞叶变性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mutations in the GRN gene encoded glycoprotein progranulin (PGRN), cause 5-10 % of all cases of frontotemporal lobar degeneration (FTLD). The aim of our study was to verify the analytical and clinical performance of an automated chemiluminescent immunoassay method for PGRN measurement recently developed (Chorus Evo, Diesse Diagnostica, Italy). METHODS: Five plasma pools and residual plasma samples (K2EDTA) from 25 control subjects (11 males, 62-79 years; 14 females, 54-76 years) and 151 patients (70 males, 53-81 years; 81 females, 44-82 years) with different neurodegenerative disorders (NDs), were assayed. In 61 out of 151 patients, genetic GRN screening was carried. RESULTS: Within-run imprecision (CV%) ranged from 3.8 % (11.5 pg/L) to 10.8 % (2.5 pg/L), and between-run, from 5.6 % (68.7 pg/L) to 10.7 % (2.8 pg/L). At genetic screening, 3 out of 61 patients were classified as GRN+ carriers, 18 as "other mutations" and 40 as "no-mutations" carriers. The PGRN median level in GRN+ carriers (15.9 pg/L) was significantly lower than that in control subjects (32.8 pg/L; p=0.006), in GRN- (27.50 pg/L; p=0.007), in other mutation carriers (24.80 pg/L; p=0.05) and in NDs patients (22.40 pg/L; p=0.05) ROC analysis, demonstrates the accuracy of progranulin levels in discriminating between "GRN+" and "GRN-" carriers (AUC 0.985) as well as "GRN+" and "other mutations" carriers (AUC 0.870). CONCLUSIONS: The new automated progranulin method, for robust analytical performance, is suitable for use in the clinical setting, supporting clinicians in making a differential diagnosis in patients with neurodegenerative disorder.
引用
- Cosma C, Talli I, Pangrazzi E, et al. Progranulin measurement with a new automated method: a step forward in the diagnostic approach to neurodegenerative disorders. Clin Chem Lab Med. 2025. PMID: 39819746. doi:10.1515/cclm-2024-1143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。